| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Dictamine modulates signaling pathways and interacts with cellular targets to exert its pharmacological effects. It promotes apoptosis and inhibits epithelial-mesenchymal transition, migration, and invasion in cancer cells. The compound exhibits anticholinesterase activity. It acts as an antifungal, vasal relaxant, and smooth muscle contractant. Dictamine’s mechanisms involve modulation of pro-inflammatory mediators and tumor cell growth in preclinical studies. The compound is a natural plant product with reported antimicrobial activity against bacteria and fungi.
|
|---|---|
| ln Vitro |
Peanut beer is susceptible to the bactericidal effects of dictamine (MIC: 64 μg/mL)[1]. In the HaCaT inflammation model, dictamine (2 μg/mL, 24 hours) can lower ROS and mitochondrial ROS as well as the production of TNF-α and IL-1β. Dictamine (0-100 μM, 12 hours) can induce cell lysis, migration, and temporary expansion of HCT116 cells, as well as HIF-1α and Slug mRNA cell proliferation [3].
In vitro, Dictamine exhibits cytotoxicity in human cervix, colon, and oral carcinoma cells. The compound shows antimicrobial activity against the model fungus Saccharomyces cerevisiae with a minimum inhibitory concentration (MIC) of 64 μg/mL. It promotes apoptosis and inhibits epithelial-mesenchymal transition, migration, and invasion in cancer cells. Dictamine displays anticholinesterase, anti-inflammatory, and antibacterial activities. It has been shown to exert cytotoxicity against various cancer cell lines in preclinical studies. |
| ln Vivo |
In the oxazolone-induced atopic dermatitis model, becamide (2 μg/mL, 200 μL, once day for 14 days) attenuates skin edema and the epidermis [2]. In the HCT116 xenograft model, becamide (50 and 100 mg/kg, lateral, three times weekly) suppresses tumor development [3]. When administered topically, becamide (1 and 5 mg/kg, 200 μL) can enhance 2,4-dinitrophenol
In vivo, Dictamine has demonstrated anti-inflammatory and anti-cancer activities in preclinical models. The compound has been investigated for its effects on pro-inflammatory mediators and tumor cell growth. Its neuroprotective properties have also been explored. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound is a natural product derived from plant sources, and its efficacy has been demonstrated in various animal models of disease. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Dictamine involve measuring its anticholinesterase activity. Enzyme inhibition is assessed using acetylcholinesterase or butyrylcholinesterase with appropriate substrates, and IC50 values are calculated from dose-response curves. For antimicrobial activity, minimum inhibitory concentration (MIC) assays are performed against bacterial and fungal cultures. Binding to cellular targets involved in cancer cell proliferation and migration may be assessed using receptor binding or kinase activity assays. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
Western Blot Analysis[3]
Cell Types: HCT116 Cell Tested Concentrations: 0-100 μM Incubation Duration: 12 hrs (hours) Experimental Results: Inhibition of HIF-1α (synthesis but not degradation) and Slug protein accumulation under hypoxic conditions. In vitro cell-based assays for Dictamine are conducted in various cancer cell lines including human cervix, colon, and oral carcinoma cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with Dictamine at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Epithelial-mesenchymal transition markers are analyzed by Western blot or qPCR. Migration and invasion are assessed using Transwell or wound healing assays. Experiments are performed in triplicate with appropriate positive and negative controls. |
| Animal Protocol |
Animal/Disease Models: HCT116 xenograft tumor model [3]
Doses: 50 and 100 mg/kg Route of Administration: po, 3 times a week. Experimental Results: Inhibit tumor growth. Reduce HIF-1α and Slug protein levels in tumor tissues. In vivo animal studies for Dictamine are conducted in rodent models of cancer or inflammation. Tumor-bearing mice are treated with Dictamine via oral administration or intraperitoneal injection. Tumor growth is monitored by caliper measurements. For anti-inflammatory evaluation, animal models of inflammation such as carrageenan-induced paw edema may be used. For neuroprotection, models of neurodegeneration may be employed. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs, and tissues are collected for histopathological and biomarker analysis at study endpoints. |
| ADME/Pharmacokinetics |
Dictamine has a molecular weight of approximately 199.21 g/mol. The compound is soluble in hot ethanol and chloroform, slightly soluble in ether, and poorly soluble in water. Its density is 1.263 g/cm³, boiling point is 343.2°C, and melting point is 133°C. Pharmacokinetic properties such as oral bioavailability, half-life, and tissue distribution would be determined in species-specific studies. The compound’s lipophilic nature suggests good membrane permeability. It shows stability under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
Studies have shown that resveratrol exhibits phototoxicity in human cell lines, particularly Jurkat T cells and HaCaT keratinocytes. Although its phototoxicity is lower than that of the structure-related furanocoumarins 5-methoxypsoralen and 8-methoxypsoralen, "due to its abundance in Rutaceae plants, it may play an important role in the development of phytophotodermatitis." (A15434) Dictamine is generally well-tolerated in preclinical studies. The compound is a natural alkaloid derived from plant sources. Its antimicrobial, anti-inflammatory, and anti-cancer activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development. |
| References |
|
| Additional Infomation |
Dictamnine alkaloid is an oxygen heterocyclic compound, an organic nitrogen heterocyclic compound, an organic heterotricyclic compound, and an alkaloid antibiotic. It has been reported to exist in Melicope triphylla, Zanthoxylum simulans, and other organisms with relevant data. Dictamnine alkaloid is a furanoquinoline alkaloid, very common in Rutaceae plants. It is the main alkaloid in the rhizome of Dictamnine dasycarpus and a major mutagenic component of the plant's crude extract. Dictamnine alkaloid has also been reported to possess phototoxicity and photomutability, participating in the plant's severe skin phototoxicity.
Dictamine is a furoquinoline alkaloid that exhibits a wide range of pharmacological activities including anti-inflammatory, anti-microbial, anti-cancer, and neuroprotective properties. It displays anticholinesterase, anti-inflammatory, mutagenic, antibacterial, and antifungal activities. Dictamine exerts cytotoxicity in human cervix, colon, and oral carcinoma cells. The compound promotes apoptosis and inhibits epithelial-mesenchymal transition, migration, and invasion in cancer cells. It has antimicrobial activity against Saccharomyces cerevisiae with an MIC of 64 μg/mL. All applications are limited to non-human research use. |
| Molecular Formula |
C12H9NO2
|
|---|---|
| Molecular Weight |
199.2
|
| Exact Mass |
199.063
|
| CAS # |
484-29-7
|
| PubChem CID |
68085
|
| Appearance |
White to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
343.2±22.0 °C at 760 mmHg
|
| Melting Point |
133.5ºC
|
| Flash Point |
161.4±22.3 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.672
|
| LogP |
2.94
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
234
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WIONIXOBNMDJFJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H9NO2/c1-14-11-8-4-2-3-5-10(8)13-12-9(11)6-7-15-12/h2-7H,1H3
|
| Chemical Name |
4-methoxyfuro[2,3-b]quinoline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~250.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0201 mL | 25.1004 mL | 50.2008 mL | |
| 5 mM | 1.0040 mL | 5.0201 mL | 10.0402 mL | |
| 10 mM | 0.5020 mL | 2.5100 mL | 5.0201 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
